Metabolite and development compound
Noribogaine
Noribogaine is often discussed beside Ibogaine, but it is not the same thing as whole-plant Iboga, extracted Ibogaine, or newer analogs. Metabolite status, drug-development claims, safety, and regulatory language need separate interpretation.
Key Points
- Noribogaine is a metabolite associated with Ibogaine, not a synonym for Iboga or Ibogaine.
- An allowed investigational study is not regulatory approval and is not proof of safety or effectiveness.
- Noribogaine claims should be read separately from Ibogaine claims and separately from analog-company claims.
- Readers can distinguish peer-reviewed data, trial registrations, agency language, press releases, patents, and investor materials.
Separate the Molecule
- Iboga is a plant and cultural subject.
- Ibogaine is an isolated alkaloid with psychoactive effects and safety risks.
- Noribogaine is a metabolite and investigational development compound.
- Analogs are designed molecules with their own pharmacology, risk, legal status, and evidence.
FDA Language
On April 24, 2026, FDA said it was allowing an early phase clinical study of Noribogaine hydrochloride to move forward after an IND submission. FDA also stated that the decision allows the study to proceed and does not mean the drug has been approved or found safe or effective.
That is a regulatory research milestone, not treatment access and not proof of efficacy.
Analog Development in This Lane
Noribogaine sits next to a set of designed analogs that are not interchangeable with iboga or ibogaine. The first-generation analog 18-MC (18-methoxycoronaridine), characterized by Stanley Glick and Martin Kuehne, has been developed commercially by Savant HWP. A newer non-hallucinogenic analog, tabernanthalog (TBG), was reported by David Olson's laboratory at UC Davis in Nature.
18-MC, tabernanthalog, and TBG are separate molecules with their own pharmacology and mostly preclinical evidence. Savant HWP's 18-MC program and David Olson's tabernanthalog work are analog-development history, not proof about ibogaine or noribogaine in humans.
Noribogaine Claim Checklist
- Is the claim from an agency record, trial registry, peer-reviewed paper, company release, investor material, or media interview?
- Does the claim involve alcohol use disorder, opioid use disorder, depression, TBI, pain, or another condition, and what source supports that specific condition?
- Is the source discussing Noribogaine itself, Ibogaine metabolism, or a broader class of Ibogaine-adjacent compounds?
Sources
Continue reading
Reader Boundary
Educational reference material only; not medical advice, legal advice, dosing instruction, provider referral, or emergency guidance. Emergency, treatment, and legal decisions belong with qualified professionals and local emergency systems.